Bioporto AS (OCSE:BIOPOR) EBIT: kr-87.07 Mil (TTM As of Dec. 2025)


OCSE:BIOPOR Bioporto AS OCSE:BIOPOR
69 GF Score
Price kr1.11
GF Value kr1.24
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bioporto AS EBIT?

Bioporto AS OCSE:BIOPOR -2.21% 69 EBIT is kr-87.07 Mil as of Dec. 2025. GuruFocus rates OCSE:BIOPOR with a GF Score™ of 69/100 and a GF Value™ of kr1.24 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Bioporto AS's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was kr-15.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-87.07 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioporto AS's annualized ROC % for the quarter that ended in Dec. 2025 was -180.37%. Bioporto AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -586.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bioporto AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -17.42%.


Bioporto AS  (OCSE:BIOPOR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioporto AS's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-55.976 * ( 1 - 0.73% )/( (37.346 + 24.268)/ 2 )
=-55.5673752/30.807
=-180.37 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioporto AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-61.608/( ( (6.904 + max(1.5, 0)) + (6.345 + max(6.247, 0)) )/ 2 )
=-61.608/( ( 8.404 + 12.592 )/ 2 )
=-61.608/10.498
=-586.85 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.399 + 5.613 + 11.06) - (5.228 + 0 + 19.344)
=1.5

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.437 + 9.249 + 10.214) - (14.021 + 0 + 8.632)
=6.247

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bioporto AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-87.07/499.708
=-17.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioporto AS EBIT Related Terms


Bioporto AS EBIT Historical Data

* Premium members only.

The historical data trend for Bioporto AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioporto AS EBIT Chart

Bioporto AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -62.93 -80.46 -60.64 -73.29 -87.07

Bioporto AS Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.15 -30.58 -18.18 -22.91 -15.40

OCSE:BIOPOR vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Bioporto AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioporto AS EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioporto AS's EV-to-EBIT falls into.


OCSE:BIOPOR
69GF Score
Bioporto AS OCSE:BIOPOR
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioporto AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-87.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-87.07 Mil mean?
Bioporto AS (OCSE:BIOPOR) has a EBIT of kr-87.07 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioporto AS.
Is Bioporto AS's EBIT too high?
Bioporto AS's current EBIT is kr-87.07 Mil. Overall, Bioporto AS has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's EBIT compare to TMO and DHR?
Bioporto AS's EBIT of kr-87.07 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioporto AS. Bioporto AS's current EBIT is kr-87.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Based on GuruFocus' analysis, Bioporto AS (OCSE:BIOPOR) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.24, compared to a current price of kr1.11 — trading 10.9% below its estimated fair value. The current EBIT is kr-87.07 Mil. Bioporto AS's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bioporto AS (OCSE:BIOPOR), the current EBIT is kr-87.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioporto AS (OCSE:BIOPOR) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of kr1.11 is trading 10.9% below its estimated GF Value™ of kr1.24. GuruFocus considers Bioporto AS to be Modestly Undervalued.

Key valuation signals for OCSE:BIOPOR:

  • EBIT: kr-87.07 Mil
  • GF Value™: kr1.24 vs. price of kr1.11 (10.9% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the OCSE:BIOPOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioporto AS Business Description

Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score

Get the complete analysis for OCSE:BIOPOR

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.11
Price
kr1.24
GF Value